Q2 Earnings Forecast for PolyPid Issued By Roth Capital

PolyPid Ltd. (NASDAQ:PYPD) – Equities researchers at Roth Capital issued their Q2 2025 earnings per share (EPS) estimates for PolyPid in a note issued to investors on Thursday, June 5th. Roth Capital analyst B. Pachaiyappan anticipates that the company will earn ($0.47) per share for the quarter. Roth Capital has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. Roth Capital also issued estimates for PolyPid’s Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.87) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.68) EPS.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, May 14th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.10.

Separately, HC Wainwright increased their price target on PolyPid from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Monday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $11.25.

PolyPid Stock Up 4.2%

PYPD stock opened at $3.50 on Monday. The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $35.67 million, a PE ratio of -0.70 and a beta of 1.25. The stock’s 50 day moving average is $2.76 and its 200-day moving average is $2.92. PolyPid has a twelve month low of $2.30 and a twelve month high of $4.49.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of PYPD. Rosalind Advisors Inc. increased its holdings in shares of PolyPid by 50.6% in the fourth quarter. Rosalind Advisors Inc. now owns 1,022,521 shares of the company’s stock worth $3,108,000 after buying an additional 343,353 shares during the period. AIGH Capital Management LLC increased its holdings in shares of PolyPid by 21.8% in the fourth quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock worth $2,509,000 after buying an additional 148,199 shares during the period. Finally, J. Goldman & Co LP purchased a new position in shares of PolyPid in the fourth quarter worth about $391,000. Hedge funds and other institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.